share_log

T2 Biosystems | SC 13G: Statement of acquisition of beneficial ownership by individuals-JACOB SAFIER(7.1%),NEW DIMENSIONS TRADING LTD.(7.1%)

T2 Biosystems | SC 13G: Statement of acquisition of beneficial ownership by individuals

T2 Biosystems | SC 13G:超过5%持股股东披露文件
美股SEC公告 ·  03/11 18:18

Moomoo AI 已提取核心信息

On February 20, 2024, a significant filing was made with the United States Securities and Exchange Commission (SEC) by New Dimensions Trading Ltd. and Jacob Safier, reporting a collective beneficial ownership of 350,000 shares of T2 Biosystems, Inc. This stake represents 7.1% of the company, based on the total number of shares outstanding as reported in T2 Biosystems' Proxy Statement filed on March 4, 2024. The filing, made under Schedule 13G, indicates that neither New Dimensions Trading Ltd. nor Jacob Safier, who may be deemed to beneficially own the shares due to his role as portfolio manager, have acquired the shares with the intent to change or influence the control of T2 Biosystems. The filing was certified as true and correct by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier on March 11, 2024. The joint filing agreement also indicates that any amendments to the Schedule 13G statement will be filed on behalf of both parties.
On February 20, 2024, a significant filing was made with the United States Securities and Exchange Commission (SEC) by New Dimensions Trading Ltd. and Jacob Safier, reporting a collective beneficial ownership of 350,000 shares of T2 Biosystems, Inc. This stake represents 7.1% of the company, based on the total number of shares outstanding as reported in T2 Biosystems' Proxy Statement filed on March 4, 2024. The filing, made under Schedule 13G, indicates that neither New Dimensions Trading Ltd. nor Jacob Safier, who may be deemed to beneficially own the shares due to his role as portfolio manager, have acquired the shares with the intent to change or influence the control of T2 Biosystems. The filing was certified as true and correct by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier on March 11, 2024. The joint filing agreement also indicates that any amendments to the Schedule 13G statement will be filed on behalf of both parties.
2024年2月20日,New Dimensions Trading Ltd.和Jacob Safier向美国证券交易委员会(SEC)提交了一份重要文件,报告了T2 Biosystems, Inc.35万股股份的集体实益所有权。根据T2 Biosystems于2024年3月4日提交的委托书中报告的已发行股票总数,该股份占该公司的7.1%。这份根据附表13G提交的文件表明,New Dimensions Trading Ltd.和由于担任投资组合经理而可能被视为实益拥有这些股份的雅各布·萨菲尔都没有意图改变或影响T2 Biosystems的控制权而收购这些股份。2024 年 3 月 11 日,New Dimensions Trading Ltd. 董事查娜·爱德斯坦和雅各布·萨菲尔将该文件认证为真实无误。联合申报协议还规定,对附表13G声明的任何修正都将代表双方提交。
2024年2月20日,New Dimensions Trading Ltd.和Jacob Safier向美国证券交易委员会(SEC)提交了一份重要文件,报告了T2 Biosystems, Inc.35万股股份的集体实益所有权。根据T2 Biosystems于2024年3月4日提交的委托书中报告的已发行股票总数,该股份占该公司的7.1%。这份根据附表13G提交的文件表明,New Dimensions Trading Ltd.和由于担任投资组合经理而可能被视为实益拥有这些股份的雅各布·萨菲尔都没有意图改变或影响T2 Biosystems的控制权而收购这些股份。2024 年 3 月 11 日,New Dimensions Trading Ltd. 董事查娜·爱德斯坦和雅各布·萨菲尔将该文件认证为真实无误。联合申报协议还规定,对附表13G声明的任何修正都将代表双方提交。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息